Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir, and nelfinavir in children and adults

Therapeutic Drug Monitoring

Volumn 25, Issue 5, 2003, Pages 588-592

  Walson, Philip D ^b,c   Cox, Shareen ^b   Utkin, Ilya ^a   Gerber, Nicholas ^a   Crim, Linda ^b   Brady, Michael ^b   Koranyi, Katalin ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

HIV; HPLC; Pediatrics; Protease inhibitors; Therapeutic drug monitoring (TDM)

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

ADOLESCENT; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CHILD; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG MARKETING; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RELIABILITY;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; RITONAVIR; SAQUINAVIR;

EID: 0141992207     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200310000-00008     Document Type: Article

References (24)

1. Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study. AIDS. 2000;14:1333-1339.
2. Marzolini C, Buclin T, Decosterd LA, et al. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit. 2001;23:394-398.
3. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
4. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis. 2002;34:511-518.
5. Lucas GM. Mending a broken HAART: a report from the 2nd International Workshop on Salvage Therapy. Hopkins HIV Rep. 1999;11:1,4-5.
6. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134:968-977.
7. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment. Swiss HIV Cohort Study. Lancet. 2001;358:1322-1327.
8. Back DJ, Khoo SH, Gibbons SE, et al. Therapeutic drug monitoring of antiretrovirals in human immunodeficiency virus infection. Ther Drug Monit. 2000;22:122-126.
9. Acosta EP, Gerber JG. Position paper on therapeutic drug monitoring of antiretroviral agents. AIDS Res Hum Retroviruses. 2002;18:825-834.
10. Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2002;71:122-130.
11. Dasgupta A, Okhuysen PC. Pharmacokinetic and other drug interactions in patients with AIDS. Ther Drug Monit. 2001;23:591-605.
12. Villani P, Feroggio M, Gianelli L, et al. Antiretrovirals: simultaneous determination of five protease inhibitors and three non-nucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography-mass spectrometry assay. Ther Drug Monit. 2001;23:380-388.
13. Olivier T, Arvieux C, Michelet C, et al. simultaneous quantitative assay of six hiv protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reverse-phase liquid chromatography. Ther Drug Monit. 2002;24:554-562.
14. Volosov A, Alexander C, Ting L, et al. Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 2002;35:99-103.
15. Utkin I, Cox S, Gerber N, et al. Simultaneous determination of indinavir, ritonavir, saquinavir, and nelfinavir by HPLC. Ther Drug Monit. 1999;21:56.
16. Trapnell CB, Jamis-Dow C, Klecker RW, et al. Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole. Antimicrob Agents Chemother. 1997;41:924-926.
17. Nair DR, Morris HH. Potential fluconazole-induced carbamazepine toxicity. Ann Pharmacother. 1999;33:790-792.
18. Flexner C. HIV-protease inhibitors. N Engl J Med. 1998;338:1281-1292.
19. van Heeswijk RP, Scherpbier HJ, de Koning LA, et al. The pharmacokinetics of nelfinavir in HIV-1-infected children. Ther Drug Monit. 2002;24:487-491.
20. van Rossum AM, Bergshoeff AS, Fraaij PL, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002;21:743-747.
21. Van Heeswijk RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit. 2002;24:323-331.
22. Tribut O, Arvieux C, Michelet C, et al. Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. Ther Drug Monit. 2002;24:554-562.
23. Langmann P, Zilly M, Weissbrich B, et al. Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART. Infection. 2002;30:13-16.
24. Soldin OP, Elin RJ, Soldin SJ. Therapeutic drug monitoring in human immunodeficiency virus/acquired immunodeficiency syndrome. Quo vadis? Arch Pathol Lab Med. 2003;127:102-105.